摘要
目的慢性荨麻疹患者应用枸地氯雷他定的安全性探讨。方法方便选取2019年2月—2020年2月于该院接受诊疗的106例慢性荨麻疹患者为该次研究对象,根据随机双盲法以及53例单组区间条件将患者分别归为对照组与试验组,对照组临床治疗方案为氯雷他定片,试验组临床治疗方案为枸地氯雷他定递减,统计并对比两组患者治疗前后的血清IgE水平、治疗后的症状评分以及不良反应情况。结果治疗后,试验组患者的血清IgE水平(89.31±10.06)IU/mL、风团数量评分(0.97±0.11)分、风团大小评分(0.92±0.06)分、风团持续时间评分(0.65±0.21)分、瘙痒程度评分(0.57±0.09)分,低于对照组(107.15±12.22)IU/mL、(1.16±0.17)分、(1.37±0.09)分、(0.98±0.31)分、(1.37±0.18)分,差异有统计学意义(t=8.205、6.831、30.287、6.416、28.940,P<0.05);试验组不良反应发生率3.77%与对照组15.09%比较,差异有统计学意义(χ^(2)=3.975,P<0.05)。结论枸地氯雷他定递减疗法可以有效降低慢性荨麻疹患者的血清IgE水平,纠正临床症状,且出现不良反应的风险性较低,可以为患者的预后提供较好的安全保障。
Objective To explore the safety of desloratadine citrate in patients with chronic urticaria.Methods 106 patients with chronic urticaria who were diagnosed and treated in the hospital from February 2019 to February 2020 were conveniently selected as the subjects of this study.According to the random double-blind method and 53 single-group interval conditions,the patients were classified as the control group and the experimental group,the clinical treatment plan of the control group was loratadine tablets,and the clinical treatment plan of the experimental group was desloratadine citrate.The serum IgE levels before and after treatment,the symptom scores after treatment and the adverse reaction situation of the two groups were counted and compared.Results After treatment,the experimental group patients'serum IgE level(89.31±10.06)IU/mL,wind mass score(0.97±0.11)points,wind mass score(0.92±0.06)points,wind mass duration score(0.65±0.21)points,itching degree score(0.57±0.09)points,lower than the control group(107.15±12.22)IU/mL,(1.16±0.17)points,(1.37±0.09)points,(0.98±0.31)points,(1.37±0.18)points,the difference was statistically significant(t=8.205,6.831,30.287,6.416,28.940,P<0.05);the incidence of adverse reactions in the experimental group was 3.77%compared with 15.09%in the control group,and the difference was statistically significant(χ^(2)=3.975,P<0.05).Conclusion Desloratadine citrate reduction therapy can effectively reduce the serum IgE level in patients with chronic urticaria,correct the clinical symptoms,and has a lower risk of adverse reactions,which can provide a better safety guarantee for the prognosis of patients.
作者
靳道彬
JIN Dao-bin(Department of Dermatology and Venereology,Jinxiang Hospital,Jining Medical College,Jining,Shandong Province,272200 China)
出处
《中外医疗》
2021年第6期85-87,共3页
China & Foreign Medical Treatment
关键词
慢性荨麻疹
氯雷他定
枸地氯雷他定
递减疗法
Chronic urticaria
Loratadine
Desloratadine citrate
Declining therapy
